ATE487484T1 - Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür - Google Patents

Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür

Info

Publication number
ATE487484T1
ATE487484T1 AT05812199T AT05812199T ATE487484T1 AT E487484 T1 ATE487484 T1 AT E487484T1 AT 05812199 T AT05812199 T AT 05812199T AT 05812199 T AT05812199 T AT 05812199T AT E487484 T1 ATE487484 T1 AT E487484T1
Authority
AT
Austria
Prior art keywords
atp channel
targeting
therapeutic agents
ncca
compositions
Prior art date
Application number
AT05812199T
Other languages
English (en)
Inventor
Marc Simard
Original Assignee
Univ Maryland
Us Dept Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland, Us Dept Veterans Affairs filed Critical Univ Maryland
Application granted granted Critical
Publication of ATE487484T1 publication Critical patent/ATE487484T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05812199T 2004-09-18 2005-09-16 Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür ATE487484T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61075804P 2004-09-18 2004-09-18
US69827205P 2005-07-11 2005-07-11
PCT/US2005/033194 WO2006034048A2 (en) 2004-09-18 2005-09-16 Therapeutic agents targeting the ncca-atp channel and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE487484T1 true ATE487484T1 (de) 2010-11-15

Family

ID=36090529

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05812199T ATE487484T1 (de) 2004-09-18 2005-09-16 Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür

Country Status (9)

Country Link
US (2) US7872048B2 (de)
EP (1) EP1799227B1 (de)
JP (2) JP5085326B2 (de)
AT (1) ATE487484T1 (de)
AU (1) AU2005287090A1 (de)
CA (1) CA2580606A1 (de)
DE (1) DE602005024704D1 (de)
IL (1) IL181826A0 (de)
WO (1) WO2006034048A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1529058B1 (de) * 2002-03-20 2013-11-06 University of Maryland Baltimore Nichtselektiver kationenkanal in nervenzellen und sur1-antagonisten zur behandlung von gehirnschwellung
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
DE602005023489D1 (de) * 2004-06-23 2010-10-21 Neurotec Pharma S L Zusammensetzung zur verwendung bei diagnose der akuten verletzungen des zentralen nervensystems
EP1782812A1 (de) * 2004-06-23 2007-05-09 Neurotec Pharma, S.L. Verbindungen zur behandlung von entzündungen des zentralen nervensystems
CA2580606A1 (en) * 2004-09-18 2006-03-30 University Of Maryland, Baltimore Therapeutic agents targeting the ncca-atp channel and methods of use thereof
US10583094B2 (en) 2004-09-18 2020-03-10 University Of Maryland Therapeutic methods that target the NCCA-ATP channel
EP1884244A1 (de) * 2006-08-02 2008-02-06 Assistance Publique - Hopitaux de Paris Kalium-Kanal Liganden zur Behandlung von Diabetes und neuropsychologischen Störungen
WO2008046014A1 (en) 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
CA2618099C (en) * 2007-02-09 2016-09-20 University Of Maryland, Baltimore Antagonists of a non-selective cation channel in neural cells
EP2167107B1 (de) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitoren von ncca-atp-kanälen zur therapie
PT2868315T (pt) 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
WO2009097443A2 (en) 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
EP2326318A4 (de) * 2008-09-16 2012-05-23 Univ Maryland Sur1-hemmer für therapeutische zwecke
CN103108637B (zh) 2010-07-19 2018-09-14 比根切萨彼公司 静脉内施用格列苯脲和其他药物的方法
JP2012061053A (ja) 2010-09-14 2012-03-29 Yuuki Kitaoka 投薬装置、投薬装置の作動方法及び投薬方法
EP2609914A1 (de) 2011-12-29 2013-07-03 Universitätsklinikum Hamburg-Eppendorf Neue Verfahren zur Behandlung oder Vermeidung von Neurodegeneration
ES2699646T3 (es) 2012-05-08 2019-02-12 Aeromics Inc Compuestos para uso en el tratamiento de enfermedades mediadas por acuaporina
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
HK1224228A1 (zh) 2013-11-06 2017-08-18 Aeromics, Inc. 新型制剂

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725A (en) 1848-08-22 Hydraulic ram
US871A (en) 1838-08-03 Mode of protectinc notes
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8809205D0 (en) * 1988-04-19 1988-05-25 Nye P C G Treatment of oedema
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5166162A (en) * 1990-03-02 1992-11-24 Adir Et Compagnie Pyridylsulfonylurea and pyridylsulfonylthiourea compounds
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
CA2044853C (en) * 1990-07-19 2004-11-09 Susan A. Greenfield Method for treating parkinson's disease employing an atp-sensitive potassium channel blocker
US5236932A (en) * 1990-07-19 1993-08-17 E. R. Squibb & Sons, Inc. Method for treating Parkinson's disease employing quinine
US5215985A (en) * 1990-07-20 1993-06-01 E. R. Squibb & Sons, Inc. Method for treating ischemic insult to neurons employing an ATP-sensitive potassium channel blocker
JPH06502538A (ja) * 1990-10-16 1994-03-24 ザ　チルドレンズメディカルセンターコーポレーション 上皮細胞成長因子（ｅｇｆ）との相同性をもつヘパリン結合性マイトジェン
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5916871A (en) * 1992-04-27 1999-06-29 Kansas State University Research Foundation Inhibitory factor
EP0641192B1 (de) 1992-05-18 1997-07-23 Minnesota Mining And Manufacturing Company Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
DE4430212A1 (de) * 1994-08-28 1996-02-29 Merck Patent Gmbh Ortho-substituierte Benzoesäure-Derivate
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US20010003751A1 (en) * 1995-02-22 2001-06-14 Terashita Zen-Ichi Pharmaceutical composition for treating transient ischemic attack
AUPN193095A0 (en) * 1995-03-24 1995-04-27 Polychip Pharmaceuticals Pty Ltd Potassium ion channel blockers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
EP1006798A4 (de) * 1996-09-05 2003-03-05 Massachusetts Inst Technology Zusammensetzungen und verfahren zur behandlung neurologischer störungen und neurodegenerativer erkrankungen
US5962645A (en) * 1996-10-04 1999-10-05 University Of Maryland Antiproliferative factor from patients with interstitial cystitis
AU8283898A (en) * 1997-06-30 1999-01-25 University Of Maryland At Baltimore Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis
US6679859B1 (en) * 1997-10-24 2004-01-20 Alliance Pharmaceutical Corp. Amelioration of ischemic damage using synthetic oxygen carriers
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6569845B1 (en) * 1997-12-26 2003-05-27 Mochida Pharmaceutical Co., Ltd. Neovascularization inhibitor containing dienogest as the active ingredient
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6100047A (en) * 1999-04-07 2000-08-08 Zen Bio, Inc. Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
JP2002512259A (ja) * 1998-04-17 2002-04-23 ユニバーシティ・オブ・メリーランド， ボルティモア 組換えヘパリン結合性上皮成長因子様成長因子（ｈｂ−ｅｇｆ）による間質性膀胱炎の治療方法
US6613785B2 (en) * 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
ATE332969T1 (de) 1998-10-26 2006-08-15 Avi Biopharma Inc Auf morpholin basierendes p53-antisense- oligonucleotid und dessen verwendungen
EP1147204A1 (de) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Zusammensetzung und verfahren zur in vivo und in vitro abschwächung der genexpression mittels dobbelsträngigem rna
CN1208323C (zh) * 1999-04-06 2005-06-29 三共株式会社 α－取代羧酸衍生物
WO2000069823A1 (en) * 1999-05-12 2000-11-23 Neurosearch A/S Ion channel modulating agents
CN1377354A (zh) * 1999-09-30 2002-10-30 纽罗杰有限公司 某些亚烷基二胺一取代的吡唑并[1,5－a]－1,5－嘧啶和吡唑并[1,5－a]－1,3,5－三嗪
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
WO2001047514A1 (en) * 1999-12-23 2001-07-05 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
JP2003523965A (ja) 2000-01-26 2003-08-12 シーダース シナイ メディカル センター 異常な脳領域および／または悪性腫瘍に薬剤をデリバリーするためにカリウムチャンネルアゴニストを使用する方法
EP1272630A2 (de) 2000-03-16 2003-01-08 Genetica, Inc. Methoden und zusammensetzungen zur interferenz durch rna
PT1145717E (pt) * 2000-04-13 2004-08-31 Pfizer Prod Inc Efeito sinergistico de gliburide e milrinona
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
JP2004516236A (ja) 2000-05-15 2004-06-03 スミスクライン・ビーチャム・コーポレイション 抗血栓剤
US6627636B2 (en) * 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
DE10054481A1 (de) * 2000-11-03 2002-05-08 Aventis Pharma Gmbh Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6492339B1 (en) * 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
US20030171407A1 (en) 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
EP1529058B1 (de) 2002-03-20 2013-11-06 University of Maryland Baltimore Nichtselektiver kationenkanal in nervenzellen und sur1-antagonisten zur behandlung von gehirnschwellung
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
DE602005023489D1 (de) * 2004-06-23 2010-10-21 Neurotec Pharma S L Zusammensetzung zur verwendung bei diagnose der akuten verletzungen des zentralen nervensystems
CA2580606A1 (en) 2004-09-18 2006-03-30 University Of Maryland, Baltimore Therapeutic agents targeting the ncca-atp channel and methods of use thereof
CN101466397A (zh) 2005-11-11 2009-06-24 奥罗根公司 给予胰岛素治疗与组织皱缩或萎缩有关的成人中枢神经系统疾病或病症的方法
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
US7787809B2 (en) * 2007-09-10 2010-08-31 Kabushiki Kaisha Toshiba Image forming apparatus, transfer unit thereof, and method of shifting transfer rollers thereof

Also Published As

Publication number Publication date
JP2008513478A (ja) 2008-05-01
EP1799227A4 (de) 2008-09-24
EP1799227A2 (de) 2007-06-27
US8569377B2 (en) 2013-10-29
US20110092542A1 (en) 2011-04-21
JP2012056966A (ja) 2012-03-22
DE602005024704D1 (de) 2010-12-23
EP1799227B1 (de) 2010-11-10
AU2005287090A1 (en) 2006-03-30
US7872048B2 (en) 2011-01-18
JP5085326B2 (ja) 2012-11-28
IL181826A0 (en) 2008-04-13
WO2006034048A3 (en) 2008-01-17
US20060100183A1 (en) 2006-05-11
WO2006034048A8 (en) 2007-05-03
CA2580606A1 (en) 2006-03-30
WO2006034048A2 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
ATE486606T1 (de) Therapeutische mittel zum targeting des ncca-atp- kanals und verwendungsverfahren dafür
ATE487484T1 (de) Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
ES2340179T3 (es) Antagonistas de urea del receptor p2y1 utiles en el tratamiento de afecciones tromboticas.
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EA200700251A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
MX389018B (es) Tratamiento de trastornos de adiccion y control de impulsos usando inhibidores de pde7.
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
EA200870019A1 (ru) Лактамовые соединения и способы их применения
DK1583541T3 (da) Forbindelser og fremgangsmåder til at øge neurogenese
NO20065544L (no) Urea-antagonister av P2Y1-reseptor anvendbare i behandling av trombotiske tilstander.
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
BR0315689A (pt) Alvo para terapia de dano cognitivo
BRPI0414794A (pt) oxadiazolidinadionas substituìdas
MA28279A1 (fr) Derives d&#39;indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
DE602005015319D1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
EA200970044A1 (ru) Производные пирролидина, обладающие активностью в отношении транспортера glyt1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties